Novo Nordisk (NYSE: NVO) Backs DKK 450 Million European Obesity Research Network While Pfizer Advances Monthly GLP-1 Therapy

Novo Nordisk (NYSE: NVO) Backs DKK 450 Million European Obesity Research Network While Pfizer Advances Monthly GLP-1 Therapy

Novo Nordisk’s (NYSE: NVO) majority owner, the Novo Nordisk Foundation, has launched a large pan-European research initiative targeting obesity and cardiometabolic diseases. The program, called CardioMetabolic Bridge, will commit DKK 450 million over six years to support academic research and company formation across Europe. Early research hubs are being established in London, Italy, and Germany, positioning the network to tap into some of Europ…